Nanoparticles As Targeted Therapies : A New Generation Of Cancer Treatments

1473 Words6 Pages
Name: Kevin Lam Student number: 688524 Words count for main text: Nanoparticles as Targeted Therapies: A New Generation of Cancer Treatments Abstract 1 abstract only in 2nd page 1. Introduction 2. Definition of Nanotherapy Nanotherapy is a novel therapy that depends on nanotechnology, nanomaterial and nanoparticles to improve certain drug properties (e.g. solubility, stability, half-lives, transportation, etc.) used to treat diseases (Harris et al. 2006). Moreover, the size of submicron sized molecular devices and nanoparticles are limited from 5-500nm in at least one dimension. The size of the drug is between 10-100nm in diameter, however, 20 fold in co-delivery over free CDDP drug indicated that the…show more content…
pros & cons vs single therapy) 6. Status of nanotherapy applying in hospitals Doxil is the first nano-drug that approved by the U.S. Food and Drug Administration (FDA) in 1995. It has enhanced drug release property from liposomes and higher therapeutic efficacy than administering free doxorubicin (Dox). (Zhao et al. 2013) detailed the novel encapsulation of Doxil by complexed Dox with Pluronic block copolymers – Pluronic P85 in treating A2780 human ovarian cancer xenografts. A positive result was given by increased of Dox delivery and cytotoxic effect in tumor. Also, (Krasner et al. 2012) reported Dox complexed with CAELYX (a liposome used to carry Doxil) to form pegylated liposomal doxorubicin - DOXIL/CAELYX used to treat 94 patients with advanced soft-tissue sarcoma (STS) in Phase III study. The result demonstrated DOXIL/CAELYX has lower incidence of myelosuprression, alopecia and cardiotoxicity but higher skin toxicity than free Doxil administration. Furthermore, combinations of CAELYX with myelosuppressive agents, e.g. ifofamide will be investigated in the future for treating other tumors. Abraxane is another drug formed based on nanotechnology consisting of albumin-bound PTX approved by the FDA to particularly treat solid tumor, breast cancer, pancreatic cancer and non-small-cell lung cancer (NSCLC) in metastatic condition. The idea of this drug is to reduce the neurotoxicity and severe hypersensitivity caused by the
Open Document